These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38345909)

  • 21. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B; Liu X; Gao Y; Li L; Dong Z
    Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.
    Carlsen AL; Joergensen MT; Knudsen S; de Muckadell OB; Heegaard NH
    Pancreas; 2013 Oct; 42(7):1107-13. PubMed ID: 24048453
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic cancer.
    He H; Di Y; Liang M; Yang F; Yao L; Hao S; Li J; Jiang Y; Jin C; Fu D
    Oncol Rep; 2013 Aug; 30(2):651-8. PubMed ID: 23733161
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis.
    Hanoun N; Delpu Y; Suriawinata AA; Bournet B; Bureau C; Selves J; Tsongalis GJ; Dufresne M; Buscail L; Cordelier P; Torrisani J
    Clin Chem; 2010 Jul; 56(7):1107-18. PubMed ID: 20431052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma.
    Ghassem-Zadeh S; Gaida MM; Szanyi S; Acha-Orbea H; Frossard JL; Hinz U; Hackert T; Strobel O; Felix K
    J Transl Med; 2017 Jun; 15(1):126. PubMed ID: 28578701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential MicroRNA Expression Profiles as Potential Biomarkers for Pancreatic Ductal Adenocarcinoma.
    Zhu Y; Wang J; Wang F; Yan Z; Liu G; Ma Y; Zhu W; Li Y; Xie L; Bazhin AV; Guo X
    Biochemistry (Mosc); 2019 May; 84(5):575-582. PubMed ID: 31234772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm.
    Xue Y; Abou Tayoun AN; Abo KM; Pipas JM; Gordon SR; Gardner TB; Barth RJ; Suriawinata AA; Tsongalis GJ
    Cancer Genet; 2013 Jun; 206(6):217-21. PubMed ID: 23933230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.
    Giulietti M; Occhipinti G; Principato G; Piva F
    Cell Oncol (Dordr); 2017 Apr; 40(2):181-192. PubMed ID: 28205147
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation.
    Campa D; Pastore M; Capurso G; Hackert T; Di Leo M; Izbicki JR; Khaw KT; Gioffreda D; Kupcinskas J; Pasquali C; Macinga P; Kaaks R; Stigliano S; Peeters PH; Key TJ; Talar-Wojnarowska R; Vodicka P; Valente R; Vashist YK; Salvia R; Papaconstantinou I; Shimizu Y; Valsuani C; Zambon CF; Gazouli M; Valantiene I; Niesen W; Mohelnikova-Duchonova B; Hara K; Soucek P; Malecka-Panas E; Bueno-de-Mesquita HBA; Johnson T; Brenner H; Tavano F; Fogar P; Ito H; Sperti C; Butterbach K; Latiano A; Andriulli A; Cavestro GM; Busch ORC; Dijk F; Greenhalf W; Matsuo K; Lombardo C; Strobel O; König AK; Cuk K; Strothmann H; Katzke V; Cantore M; Mambrini A; Oliverius M; Pezzilli R; Landi S; Canzian F
    Int J Cancer; 2018 Jan; 142(2):290-296. PubMed ID: 28913878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
    Brunetti O; Russo A; Scarpa A; Santini D; Reni M; Bittoni A; Azzariti A; Aprile G; Delcuratolo S; Signorile M; Gnoni A; Palermo L; Lorusso V; Cascinu S; Silvestris N
    Oncotarget; 2015 Sep; 6(27):23323-41. PubMed ID: 26259238
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Construction of a circRNA-miRNA-mRNA network to explore the pathogenesis and treatment of pancreatic ductal adenocarcinoma.
    Xiao Y
    J Cell Biochem; 2020 Jan; 121(1):394-406. PubMed ID: 31232492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA modulated networks of adaptive and innate immune response in pancreatic ductal adenocarcinoma.
    Felix TF; Lopez Lapa RM; de Carvalho M; Bertoni N; Tokar T; Oliveira RA; M Rodrigues MA; Hasimoto CN; Oliveira WK; Pelafsky L; Spadella CT; Llanos JC; F Silva G; Lam WL; Rogatto SR; Amorim LS; Drigo SA; Carvalho RF; Reis PP
    PLoS One; 2019; 14(5):e0217421. PubMed ID: 31150430
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential four‑miRNA signature associated with T stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co‑expression analysis.
    You L; Wang J; Zhang F; Zhang J; Tao H; Zheng X; Hu Y
    Mol Med Rep; 2019 Jan; 19(1):441-451. PubMed ID: 30483731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Malignancy in chronic pancreatitis: analysis of diagnostic procedures and proposal of a clinical algorithm.
    Rückert F; Brussig T; Kuhn M; Kersting S; Bunk A; Hunger M; Saeger HD; Niedergethmann M; Post S; Grützmann R
    Pancreatology; 2013; 13(3):243-9. PubMed ID: 23719595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of potential serum exosomal microRNAs involved in acinar-ductal metaplasia that is a precursor of pancreatic cancer associated with chronic pancreatitis.
    Sheng LP; Han CQ; Nie C; Xu T; Zhang K; Li XJ; Xie XR; Lin R; Ding Z
    Medicine (Baltimore); 2021 May; 100(18):e25753. PubMed ID: 33950960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
    Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
    Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
    Shaw VE; Lane B; Jenkinson C; Cox T; Greenhalf W; Halloran CM; Tang J; Sutton R; Neoptolemos JP; Costello E
    Mol Cancer; 2014 May; 13():114. PubMed ID: 24884871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of MSX2 mRNA in brush cytology specimens distinguished pancreatic carcinoma from chronic pancreatitis.
    Satoh K; Hamada S; Kanno A; Ishida K; Ito H; Hirota M; Masamune A; Egawa S; Unno M; Shimosegawa T
    Cancer Sci; 2011 Jan; 102(1):157-61. PubMed ID: 20961362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific MAPK-Associated MicroRNAs in Serum Differentiate Pancreatic Cancer from Autoimmune Pancreatitis.
    Akamatsu M; Makino N; Ikeda Y; Matsuda A; Ito M; Kakizaki Y; Saito Y; Ishizawa T; Kobayashi T; Furukawa T; Ueno Y
    PLoS One; 2016; 11(7):e0158669. PubMed ID: 27380024
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3.
    Wang C; Liu P; Wu H; Cui P; Li Y; Liu Y; Liu Z; Gou S
    Oncotarget; 2016 Mar; 7(12):14912-24. PubMed ID: 26908446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.